Is Testosterone Safe After Multiple Myeloma?
Timeline
Video Summary
A history of multiple myeloma raises important questions before an older man considers testosterone therapy. Dr. O’Connor addresses a 79-year-old man asking whether his age and history of multiple myeloma make TRT unsafe and what a safe testosterone dose might be. He emphasizes that determining whether the cancer is active and understanding the man’s complete medical history are essential parts of evaluating the question.
A major focus is anemia, which can occur with chronic disease, cancer, cancer treatment, aging, nutritional problems, and other causes. Dr. O’Connor discusses the importance of determining the type and cause of anemia rather than treating a low blood count in isolation. He states that he is not aware of data showing testosterone grows multiple myeloma and discusses circumstances in which an anemic man may ask his healthcare providers whether testosterone could be considered.
Dr. O’Connor stresses that testosterone decisions in someone with a cancer history require appropriate medical evaluation and coordination with physicians who understand the underlying disease. He recommends involvement from internal medicine and the oncologist who treated the multiple myeloma rather than approaching TRT as an isolated hormone decision.
The discussion broadens to the ABCDs™ and the importance of assessing hemoglobin A1C, kidney function, blood pressure, cardiovascular health, hemoglobin, hematocrit, and other health factors before starting testosterone at an advanced age. Dr. O’Connor also distinguishes multiple myeloma from prostate cancer and explains that testosterone use in a patient with prostate cancer requires particularly careful case-by-case consideration and collaboration with urology.
Dr. O’Connor reviews several testosterone formulations, including injections, gels, oral testosterone undecanoate, pellets, and longer-acting testosterone undecanoate injections. He discusses testosterone cypionate and enanthate as injectable options and explains that the appropriate treatment and dose must be individualized by the healthcare provider.
The central message is that chronological age alone does not answer whether TRT is appropriate. Dr. O’Connor emphasizes evaluating cancer status, anemia, cardiovascular health, kidney function, blood pressure, medications, laboratory results, and the man's overall health before deciding whether testosterone can be used safely.
Drug Callouts
Condition Callouts
Key Takeaways
- A history of multiple myeloma does not make chronological age alone sufficient to determine whether testosterone therapy is appropriate.
- Dr. O’Connor says he is not aware of data showing that testosterone causes multiple myeloma to grow or accelerates the disease.
- Anemia should be evaluated for its underlying cause, including chronic disease, cancer treatment, nutritional deficiencies, and bone marrow disorders.
- Hemoglobin, hematocrit, MCV, cardiovascular health, blood pressure, kidney function, and metabolic health are important considerations before TRT.
- Men with a history of cancer should involve physicians familiar with their cancer and overall medical condition when considering testosterone.
- Testosterone is available in several formulations, but the appropriate treatment and dose must be individualized to the patient.